Literature DB >> 10202368

Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis.

P H Verin1, I D Dicker, B Mortemousque.   

Abstract

BACKGROUND: Vernal keratoconjunctivitis (VKC) is a severe though transient form of ocular allergy, predominant in young males, which requires careful management. Corticosteroids are effective but also cause serious topical side-effects in the eye, such as glaucoma and cataracts. The safer, mast cell stabilizing anti-inflammatories (commonly sodium cromoglycate) therefore have an important role. This parallel group study compared efficacy, tolerability and safety of sodium cromoglycate 2% with nedocromil sodium 2%, administered as one drop per eye four times daily for a period of 5 months.
METHODS: Children aged 4-17 years, with a diagnosis of mostly limbal VKC in the last 12 months, entered a 2-week baseline during which they used only artificial tears, and were then randomized to treatment, in groups of 18, on an investigator single-masked basis. Daily symptom diary cards were kept by patients/guardians, and VKC was assessed by the clinician at approximately monthly intervals. Dexamethasone was provided for rescue control of severe symptoms, if needed.
RESULTS: A total of 34 patients completed the study. Both trial treatments produced rapid improvements and many ocular signs and symptoms, including Trantas' dots, chemosis, itching, soreness and sticky discharge, were fully controlled by the end of the study. However, nedocromil sodium took effect more quickly, with a significant reduction compared to sodium cromoglycate for itching, grittiness, hyperaemia and keratitis within 6 weeks. In addition, nedocromil sodium was the more efficacious overall (significant vs sodium cromoglycate for hyperaemia, keratitis, papillae and pannus at 22 weeks). Both treatments were well tolerated and without serious adverse effects. Final opinions favoured nedocromil sodium, with full control of VKC recorded for 94% (patient opinion) and 100% (clinician opinion) of this treatment group, compared with 29% and 0%, respectively, in the sodium cromoglycate group.
CONCLUSIONS: Nedocromil sodium 2% eye drops is significantly more effective than sodium cromoglycate for treatment of VKC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202368     DOI: 10.1046/j.1365-2222.1999.00501.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

Review 1.  Overview of ocular allergy treatment.

Authors:  M Friedlaender
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

Review 2.  Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis.

Authors:  F Mantelli; M S Santos; T Petitti; R Sgrulletta; M Cortes; A Lambiase; S Bonini
Journal:  Br J Ophthalmol       Date:  2007-06-22       Impact factor: 4.638

3.  Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.

Authors:  Veysi Oner; Fatih Mehmet Türkcü; Mehmet Taş; Mehmet Fuat Alakuş; Yalçın Işcan
Journal:  Jpn J Ophthalmol       Date:  2012-05-25       Impact factor: 2.447

Review 4.  Ocular allergy in pediatric practice.

Authors:  Mark B Abelson; David Granet
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

Review 5.  Therapeutic Targets in Allergic Conjunctivitis.

Authors:  Bisant A Labib; DeGaulle I Chigbu
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-28

Review 6.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders.

Authors:  Leonard Bielory; C H Katelaris; Susan Lightman; Robert M Naclerio
Journal:  MedGenMed       Date:  2007-08-15

Review 8.  [Therapeutic options in vernal keratoconjunctivitis].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.